Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||transitional cell carcinoma||not applicable||Ascrinvacumab||Phase II||Actionable||In a Phase II trial, PF-03446962 demonstrated multiple toxicities and limited efficacy in patients with urothelial cancer (PMID: 24566706).||24566706|